MA33471B1 - Formulation sous-cutanée d'anticorps anti-her2 - Google Patents

Formulation sous-cutanée d'anticorps anti-her2

Info

Publication number
MA33471B1
MA33471B1 MA34587A MA34587A MA33471B1 MA 33471 B1 MA33471 B1 MA 33471B1 MA 34587 A MA34587 A MA 34587A MA 34587 A MA34587 A MA 34587A MA 33471 B1 MA33471 B1 MA 33471B1
Authority
MA
Morocco
Prior art keywords
formulations
relates
mixture
effective amount
formulation
Prior art date
Application number
MA34587A
Other languages
Arabic (ar)
English (en)
Inventor
Michael Adler
Ulla Grauschopf
Hanns-Christian Mahler
Oliver Boris Stauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43500473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33471(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33471B1 publication Critical patent/MA33471B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique stable hautement concentrée d'un anticorps anti-HER2 pharmaceutiquement actif, tel que par exemple le Trastuzumab (HERCEPIN"), le Pertuzumab ou le T-DM1, ou un mélange de telles molécules d'anticorps destinées à être injectées de manière sous-cutanée. En particulier, la présente invention concerne des formulations comprenant, en plus d'une quantité appropriée de l'anticorps anti-HER2, une quantité efficace d'au moins une enzyme hyaluronidase sous la forme d'une formulation combinée ou destinées à être utilisées sous la forme d'une co-formulation. Lesdites formulations comprenant de plus au moins un agent tampon, tel que par exemple un tampon histidine, un agent stabilisant ou un mélange de deux ou plusieurs stabilisants (par exemple un glucide, tel que par exemple le dihydrate de ±,±-tréhalose ou le sucrose, et éventuellement de la méthionine comme second agent stabilisant), un tensioactif non ionique et une quantité efficace d'au moins une enzyme hyaluronidase. L'invention concerne également des procédés de préparation de telles formulations et leurs utilisations.
MA34587A 2009-07-31 2010-07-28 Formulation sous-cutanée d'anticorps anti-her2 MA33471B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09167025 2009-07-31
PCT/EP2010/060930 WO2011012637A2 (fr) 2009-07-31 2010-07-28 Formulation sous-cutanée d'anticorps anti-her2

Publications (1)

Publication Number Publication Date
MA33471B1 true MA33471B1 (fr) 2012-07-03

Family

ID=43500473

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34587A MA33471B1 (fr) 2009-07-31 2010-07-28 Formulation sous-cutanée d'anticorps anti-her2

Country Status (41)

Country Link
US (9) US9345661B2 (fr)
EP (4) EP2687202B1 (fr)
JP (2) JP5462944B2 (fr)
KR (2) KR101769652B1 (fr)
CN (3) CN113967194A (fr)
AR (2) AR077605A1 (fr)
AU (1) AU2010277657B2 (fr)
BR (1) BR112012002080A2 (fr)
CA (1) CA2768458C (fr)
CL (2) CL2012000269A1 (fr)
CO (1) CO6430421A2 (fr)
CR (1) CR20110679A (fr)
CY (1) CY1114185T1 (fr)
DK (3) DK2687202T3 (fr)
DO (1) DOP2015000255A (fr)
EA (2) EA031013B1 (fr)
EC (2) ECSP12011643A (fr)
ES (2) ES2413090T5 (fr)
FI (1) FI2687202T3 (fr)
GT (1) GT201200024A (fr)
HK (1) HK1215157A1 (fr)
HR (2) HRP20230462T1 (fr)
HU (1) HUE062122T2 (fr)
IL (2) IL217382A (fr)
IN (1) IN2012CN00961A (fr)
LT (1) LT2687202T (fr)
MA (1) MA33471B1 (fr)
MX (2) MX355450B (fr)
MY (2) MY163001A (fr)
NZ (2) NZ597190A (fr)
PE (2) PE20131324A1 (fr)
PL (2) PL2687202T3 (fr)
PT (2) PT2459167E (fr)
RS (2) RS52913B2 (fr)
SG (2) SG178185A1 (fr)
SI (2) SI2459167T2 (fr)
TN (1) TN2012000023A1 (fr)
TW (2) TWI474834B (fr)
UA (2) UA102166C2 (fr)
WO (1) WO2011012637A2 (fr)
ZA (2) ZA201109459B (fr)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1850874B1 (fr) 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20120177640A1 (en) * 2009-07-24 2012-07-12 Josef Burg Optimizing the production of antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
AR090244A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
EP2849723B1 (fr) 2012-05-18 2018-05-02 Genentech, Inc. Formulations d'anticorps monoclonal à concentration élevée
EP2864346B1 (fr) 2012-06-21 2018-10-17 Synthon Biopharmaceuticals B.V. Procédé de purification d'un anticorps
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
KR101454646B1 (ko) * 2012-11-05 2014-10-27 (주)한국비엠아이 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
DK2934582T3 (da) * 2012-12-21 2020-02-24 Ichnos Sciences SA Anti-her2-antistofformulering
CN110538322A (zh) * 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015130173A1 (fr) 2014-02-28 2015-09-03 Merus B.V. Anticorps qui se lie à erbb-2 et erbb-3
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
CN104906576B (zh) * 2014-03-13 2018-06-19 四川科伦博泰生物医药股份有限公司 可供皮下注射的高浓度抗vegf抗体配制剂
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157947A1 (fr) 2014-06-23 2017-04-26 Novartis AG Polypeptide de fusion hsa-gdf-15 et son utilisation
SG11201609706VA (en) 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
CN106794247B (zh) 2014-09-15 2022-12-02 豪夫迈·罗氏有限公司 抗体配制剂
CN107406506A (zh) 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
US9824394B1 (en) 2015-02-06 2017-11-21 Square, Inc. Payment processor financing of customer purchases
US9779432B1 (en) 2015-03-31 2017-10-03 Square, Inc. Invoice financing and repayment
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
WO2016196373A2 (fr) 2015-05-30 2016-12-08 Genentech, Inc. Procédés de traitement de cancer du sein métastatique her2 positif
IL256242B2 (en) * 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (fr) * 2015-07-02 2017-01-05 주식회사 녹십자 Agent thérapeutique et procédé de traitement de maladie de hunter
CN106999591B (zh) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
CA3004152C (fr) * 2015-11-03 2024-04-16 Janssen Biotech, Inc. Formulations sous-cutanee d'anticorps anti-cd38 et leurs utilisations
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3479819B1 (fr) 2016-06-30 2024-01-24 Celltrion Inc. Préparation pharmaceutique liquide stable
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
MA46761A (fr) * 2016-11-10 2019-09-18 Translate Bio Inc Administration sous-cutanée d'arn messager
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
EP3562844A1 (fr) 2016-12-28 2019-11-06 Genentech, Inc. Traitement du cancer exprimant her2 avancé
TW202508629A (zh) * 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
WO2018200505A1 (fr) 2017-04-24 2018-11-01 Genentech, Inc. Mutations erbb2/her2 dans le domaine transmembranaire ou juxtamembranaire
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP3630827A1 (fr) * 2017-06-02 2020-04-08 H. Hoffnabb-La Roche Ag Voies d'administration pour des agonistes immunitaires
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
US11506668B2 (en) * 2017-06-23 2022-11-22 Engebraaten Olav Diagnosis and treatment of cancer
WO2019020745A1 (fr) * 2017-07-28 2019-01-31 F. Hoffmann-La Roche Ag Formulation d'anticorps bispécifique
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
EP3681908A1 (fr) 2017-09-13 2020-07-22 Teneobio, Inc. Anticorps à chaîne lourde se liant à des exoenzymes
EA202090731A1 (ru) * 2017-09-15 2020-06-11 Эмджен Инк. Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
CN107898756B (zh) * 2017-12-22 2020-11-20 东曜药业有限公司 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用
WO2019123427A1 (fr) 2017-12-22 2019-06-27 Novartis Ag Procédés de traitement de troubles métaboliques avec des variants de fgf21
CN111683966B (zh) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
US20210379186A1 (en) * 2018-04-16 2021-12-09 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
EP3560945A1 (fr) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Procédés de purification de polypeptides utilisant des polysorbates
UA130542C2 (uk) 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
KR102934808B1 (ko) 2018-07-19 2026-03-05 (주)셀트리온 안정한 액체 약제학적 제제
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
MX2021002764A (es) 2018-09-12 2021-05-12 Silverback Therapeutics Inc Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
WO2020060183A1 (fr) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 Formation de liquide pour stabiliser un anticorps de trastuzumab
WO2020081408A1 (fr) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations d'anticorps anti-rsv et leurs procédés d'utilisation
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (fr) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3876978A4 (fr) * 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. Formulations stables d'anticorps du récepteur de mort programmé 1 (mp-1) et leurs méthodes d'utilisation
CN111202845A (zh) * 2018-11-22 2020-05-29 上海医药集团股份有限公司 包含抗cd20抗体的药物配制剂及其制备方法和应用
EP3887393A1 (fr) 2018-11-26 2021-10-06 Novartis AG Polypeptides de fusion de lpl-gpihbp1
WO2020142583A1 (fr) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'inhibiteurs de parp et de radioconjugués d'anticorps
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
KR102650991B1 (ko) * 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
WO2020206330A1 (fr) 2019-04-05 2020-10-08 Teneobio, Inc. Anticorps à chaîne lourde se liant à psma
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
KR20220035908A (ko) 2019-06-19 2022-03-22 실버백 테라퓨틱스, 인크. 항-메소텔린 항체 및 이의 면역접합체
WO2021022304A2 (fr) 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. COMPOSÉS DE LIAISON MULTISPÉCIFIQUES QUI SE LIENT À LRRC15 ET CD3ε
WO2021023267A1 (fr) * 2019-08-07 2021-02-11 信达生物制药(苏州)有限公司 Préparation comprenant un anticorps bispécifique anti-pd 1/her2, son procédé de préparation et son utilisation
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
WO2021079337A1 (fr) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Formulation pharmaceutique d'anticorps anti-her2 et sa préparation
EP4058024A1 (fr) 2019-11-15 2022-09-21 Seagen Inc. Méthodes de traitement du cancer du sein her2 positif avec du tucatinib en combinaison avec un conjugué médicament-anticorps anti-her2
KR20210059646A (ko) * 2019-11-15 2021-05-25 삼성바이오에피스 주식회사 항체 의약품용 액상 조성물
CA3152314A1 (fr) * 2019-11-15 2021-05-20 Andrea ALLMENDINGER Prevention de la formation de particules visibles dans des solutions de proteines aqueuses
KR20220113414A (ko) * 2019-12-09 2022-08-12 제넨테크, 인크. 항-pd-l1 항체 제제
CU20190104A7 (es) 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
CN115023441A (zh) 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
IL296119A (en) * 2020-03-04 2022-11-01 Shanghai Henlius Biotech Inc Pharmaceutical formulation comprising bevacizumab
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
TW202330622A (zh) 2020-04-29 2023-08-01 美商泰尼歐生物公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
CN113797161A (zh) * 2020-06-11 2021-12-17 上海宝济药业有限公司 一种重组人透明质酸酶的液体制剂及其应用
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
CN113827718A (zh) * 2020-06-24 2021-12-24 上海宝济药业有限公司 一种含有透明质酸酶的制剂及其应用
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
CN116472049A (zh) 2020-06-30 2023-07-21 特尼奥生物股份有限公司 与bcma结合的多特异性抗体
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
US12221638B2 (en) 2020-08-07 2025-02-11 Alteogen Inc. Method for producing recombinant hyaluronidase
CA3191224A1 (fr) 2020-10-16 2022-04-21 Shenda GU Composes de liaison multispecifiques se liant a pd-l1
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
JP2024501721A (ja) * 2020-12-30 2024-01-15 上海宝済薬業股▲ふん▼有限公司 組換えヒトヒアルロニダーゼ製剤およびその用途
CN114762677A (zh) * 2020-12-30 2022-07-19 上海宝济药业有限公司 一种重组人透明质酸酶制剂及其应用
IL305265A (en) * 2021-02-19 2023-10-01 Inhibrx Inc Preparations of DR5-binding polypeptides
JP2024510111A (ja) * 2021-02-23 2024-03-06 江蘇康寧杰瑞生物制薬有限公司 腫瘍の予防、軽減、又は治療方法
KR20230148828A (ko) 2021-02-25 2023-10-25 테네오바이오, 인코포레이티드 항-psma 항체 및 car-t 구조
US20240182597A1 (en) 2021-02-26 2024-06-06 Teneobio, Inc. Anti-muc1-c antibodies and car-t structures
KR20230159476A (ko) 2021-03-23 2023-11-21 킹즈 컬리지 런던 NKG2D, CXCR2 및 dap10/dap12 융합 폴리펩티드를 포함하는 조성물 및 이의 사용 방법
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
KR20230166090A (ko) 2021-04-06 2023-12-06 테네오바이오, 인코포레이티드 항-cd19 항체 및 car-t 구조체
CN117337303A (zh) 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
WO2022271987A1 (fr) 2021-06-23 2022-12-29 TeneoFour, Inc. Anticorps anti-cd38 et leurs épitopes
WO2023004197A1 (fr) 2021-07-23 2023-01-26 Teneoten, Inc. Anticorps à chaîne lourde se liant à l'antigène de surface de l'hépatite b
WO2023019556A1 (fr) * 2021-08-20 2023-02-23 齐鲁制药有限公司 Préparation d'anticorps anti-her2 à haute concentration et son utilisation
MX2024004550A (es) 2021-10-14 2024-04-29 Teneobio Inc Proteinas de union a la mesotelina y usos de las mismas.
TWI864690B (zh) * 2022-04-22 2024-12-01 台康生技股份有限公司 用於皮下投予之包含抗-her2抗體的藥學組合物
US20260035478A1 (en) 2022-07-27 2026-02-05 Teneobio, Inc. Mesothelin binding proteins and uses thereof
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
EP4598958A1 (fr) 2022-10-05 2025-08-13 Amgen Inc. Polythérapies comprenant des thérapies de redirection de lymphocytes t et des anticorps agonistes anti-il-2r ou des fragments de ceux-ci
EP4389762A1 (fr) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibiteurs de l'activité de dux4 et leur utilisation en thérapie.
AU2024226156A1 (en) 2023-02-21 2025-08-28 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
CN121152802A (zh) 2023-04-18 2025-12-16 魁尔斯弗生物治疗股份有限公司 与ly6g6d结合的抗体
WO2025158306A1 (fr) * 2024-01-25 2025-07-31 Intas Pharmaceuticals Ltd. Nouvelle formulation de phesgo à haute concentration
WO2025168089A1 (fr) * 2024-02-08 2025-08-14 上海宝济药业股份有限公司 Combinaison pharmaceutique pour administration sous-cutanée et utilisation associée
WO2025196207A1 (fr) 2024-03-20 2025-09-25 King's College London Compositions et procédés destinés à être utilisés dans la déplétion de cellules sénescentes et le traitement du vieillissement
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體
TW202544034A (zh) 2024-05-06 2025-11-16 美商榮都醫療公司 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
WO2025245354A1 (fr) * 2024-05-22 2025-11-27 Halozyme, Inc. Polythérapie avec du dupilumab et des hyaluronidases
WO2025249934A1 (fr) * 2024-05-29 2025-12-04 (주)알테오젠 Composition pharmaceutique pour injection sous-cutanée comprenant un antagoniste du récepteur de l'hormone de croissance et un support à action prolongée
WO2025264960A1 (fr) * 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Anticorps qui se lient à il -13 et anticorps qui se lient à ox40l
WO2025264972A1 (fr) * 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Anticorps se liant à il -4 ralpha et anticorps se liant

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533A (en) 1837-12-26 Truss for hermta
US4943A (en) 1847-01-26 Harness-buckle
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0171407B1 (fr) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Ameliorations relatives aux facteurs de croissance
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0491007B1 (fr) 1989-09-08 1996-03-13 The Johns Hopkins University Modifications structurelles du gene recepteur du facteur de croissance epidermique dans les gliomes humains
WO1991005264A1 (fr) 1989-09-29 1991-04-18 Oncogenetics Partners Detection et quantification des proteines apparentees neu dans les liquides biologiques des humains
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
WO1996003397A1 (fr) 1994-07-21 1996-02-08 Akzo Nobel N.V. Formulations de peroxides cetoniques cycliques
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5573186A (en) 1995-03-20 1996-11-12 Moen Incorporated Stationary venturi diverter valve
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
CA2407556C (fr) 2000-05-19 2011-06-21 Genentech, Inc. Analyse de detection genique permettant d'ameliorer la probabilite d'une reponse efficace a une therapie du cancer basee sur un antagoniste d'erbb
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
CA2953239A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Cellules produisant des compositions d'anticorps
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10153197A1 (de) 2001-10-27 2003-05-08 Merck Patent Gmbh Pigment mit Metallglanz
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
TW555245U (en) 2003-01-29 2003-09-21 Hon Hai Prec Ind Co Ltd Cable connector assembly
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US20050180952A1 (en) 2003-08-26 2005-08-18 Pettis Ronald J. Methods for intradermal delivery of therapeutics agents
MXPA06004418A (es) 2003-10-24 2006-07-06 Mdc Invest Holdings Inc Jeringa de mezclado de camara dual y metodo de uso.
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
EP1850874B1 (fr) 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007074880A1 (fr) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Préparation stabilisatrice contenant des anticorps
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP2009531371A (ja) 2006-03-28 2009-09-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
JP5070993B2 (ja) 2007-08-27 2012-11-14 富士通株式会社 音処理装置、位相差補正方法及びコンピュータプログラム
JP2011500086A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
BRPI0820819B1 (pt) 2007-12-21 2021-06-08 F. Hoffmann-La Roche Ag formulação de anticorpos humanizados b-ly 1 e seu uso
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
AU2009290976B2 (en) 2008-09-10 2015-05-28 F. Hoffmann-La Roche Ag Delivery device for use with a therapeutic drug
US7905299B2 (en) 2008-09-18 2011-03-15 Longyear Tm, Inc. Articulation assembly for moving a drill mast
ES2531385T3 (es) 2008-09-19 2015-03-13 Hoffmann La Roche Formulación que comprende un anticuerpo contra la selectina P
WO2010138918A1 (fr) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase comme adjuvant pour augmenter le volume d'injection et la dispersion de vésicules membranaires synthétiques de grand diamètre contenant un agent thérapeutique
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG178226A1 (en) 2009-08-04 2012-03-29 Genentech Inc Concentrated polypeptide formulations with reduced viscosity
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
TW202508629A (zh) 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
KR102650991B1 (ko) 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
JP2023533813A (ja) 2020-07-14 2023-08-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 一定用量配合剤のアッセイ
KR20240163084A (ko) 2022-03-14 2024-11-18 제넨테크, 인크. 유방암에 대한 복합 요법

Also Published As

Publication number Publication date
HRP20230462T1 (hr) 2023-07-21
CL2013002550A1 (es) 2013-12-13
EP4339212A3 (fr) 2024-06-19
KR101769652B1 (ko) 2017-08-18
US20240207400A1 (en) 2024-06-27
US20110044977A1 (en) 2011-02-24
ES2413090T5 (es) 2022-05-03
CA2768458A1 (fr) 2011-02-03
EA201200204A1 (ru) 2012-08-30
WO2011012637A4 (fr) 2011-11-03
DOP2015000255A (es) 2016-01-31
IL253941B (en) 2021-10-31
JP2013500947A (ja) 2013-01-10
CL2012000269A1 (es) 2012-10-12
US9345661B2 (en) 2016-05-24
TN2012000023A1 (en) 2013-09-19
EP2687202A1 (fr) 2014-01-22
GT201200024A (es) 2013-10-28
US20130216532A1 (en) 2013-08-22
AR108936A2 (es) 2018-10-10
MX355450B (es) 2018-04-18
US20180228895A1 (en) 2018-08-16
IN2012CN00961A (fr) 2013-05-24
CA2768458C (fr) 2013-12-03
KR101413947B1 (ko) 2014-06-30
PE20120665A1 (es) 2012-06-01
US20210353753A1 (en) 2021-11-18
RS64314B1 (sr) 2023-08-31
AU2010277657B2 (en) 2013-05-02
AU2010277657A1 (en) 2012-02-02
US12427193B2 (en) 2025-09-30
IL253941A0 (en) 2017-10-31
CN102573789B (zh) 2015-09-30
ECSP12011643A (es) 2012-02-29
US20160166689A1 (en) 2016-06-16
JP2013224305A (ja) 2013-10-31
EP2459167B1 (fr) 2013-05-15
EA027553B1 (ru) 2017-08-31
HRP20130697T4 (hr) 2022-04-29
DK2687202T3 (da) 2023-07-10
EP4257150A8 (fr) 2025-08-13
PL2687202T3 (pl) 2023-07-24
IL217382A0 (en) 2012-02-29
EP4257150A2 (fr) 2023-10-11
US9968676B2 (en) 2018-05-15
WO2011012637A2 (fr) 2011-02-03
SI2687202T1 (sl) 2023-07-31
UA104254C2 (ru) 2014-01-10
RS52913B2 (sr) 2022-05-31
HK1215157A1 (zh) 2016-08-19
SI2459167T1 (sl) 2013-07-31
CN102573789A (zh) 2012-07-11
NZ597190A (en) 2012-12-21
TW201328708A (zh) 2013-07-16
ZA201207815B (en) 2013-07-31
CN105168125A (zh) 2015-12-23
MX2012001124A (es) 2012-03-29
EA031013B1 (ru) 2018-11-30
ZA201109459B (en) 2013-05-29
EP4339212B1 (fr) 2025-06-25
KR20130041374A (ko) 2013-04-24
EP2687202B1 (fr) 2023-05-10
DK4339212T3 (da) 2025-08-25
JP5878144B2 (ja) 2016-03-08
HRP20130697T1 (en) 2013-09-30
WO2011012637A3 (fr) 2011-08-25
TWI474834B (zh) 2015-03-01
AR077605A1 (es) 2011-09-07
ES2948033T3 (es) 2023-08-30
HK1172236A1 (en) 2013-04-19
SI2459167T2 (sl) 2022-05-31
PL2459167T5 (pl) 2023-12-11
MY163001A (en) 2017-07-31
FI2687202T3 (fi) 2023-06-21
SG178185A1 (en) 2012-03-29
CN113967194A (zh) 2022-01-25
LT2687202T (lt) 2023-07-10
PT2459167E (pt) 2013-06-24
EP4339212A2 (fr) 2024-03-20
EA201400270A1 (ru) 2014-06-30
EP4257150A3 (fr) 2023-11-01
PL2459167T3 (pl) 2013-10-31
ES2413090T3 (es) 2013-07-15
SG193146A1 (en) 2013-09-30
PT2687202T (pt) 2023-06-15
NZ603900A (en) 2014-03-28
PE20131324A1 (es) 2013-11-04
ECSP23041058A (es) 2023-07-31
CY1114185T1 (el) 2016-08-31
EP2459167B2 (fr) 2022-03-02
US20250121059A1 (en) 2025-04-17
JP5462944B2 (ja) 2014-04-02
RS52913B (sr) 2014-02-28
DK2459167T3 (da) 2013-06-03
CR20110679A (es) 2012-03-06
EP2459167A2 (fr) 2012-06-06
UA102166C2 (ru) 2013-06-10
TWI401089B (zh) 2013-07-11
CO6430421A2 (es) 2012-04-30
IL217382A (en) 2017-09-28
MY172245A (en) 2019-11-19
KR20120038540A (ko) 2012-04-23
TW201106973A (en) 2011-03-01
US20260007743A1 (en) 2026-01-08
HUE062122T2 (hu) 2023-09-28
US20250090660A1 (en) 2025-03-20
BR112012002080A2 (pt) 2016-04-12

Similar Documents

Publication Publication Date Title
MA33471B1 (fr) Formulation sous-cutanée d'anticorps anti-her2
MA33592B1 (fr) Formulations pharmaceutiques hautement concentrées
WO2008150479A3 (fr) Formulation de peptide stable à haute température
NZ596367A (en) Lyophilized therapeutic peptibody formulations
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA35136B1 (fr) Formulation pour un anticorps anti-a4b7
WO2010100200A3 (fr) Préparation d'anticorps lyophilisée
NZ606283A (en) Stable antibody compositions and methods for stabilizing same
NZ600096A (en) Formulations of antibody
MA35904B1 (fr) Formulations stabilisées contenant des anticorps anti-ang2
AR067011A1 (es) Formulaciones de anticuerpos
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
MX2022008949A (es) Formulacion de anticuerpos estable.
BR112022022620A2 (pt) Formulações de anticorpos anti-il-33
JOP20240024A1 (ar) صياغات الأجسام المضادة
MA53977B1 (fr) Compositions stables du sémaglutide et leurs utilisations
AR127813A1 (es) FORMULACIONES FARMACEUTICAS QUE COMRENDEN Fab-PEG
TH138064A (th) สูตรตำรับแอนทิบอดีแอนทิ-her2 ใต้หนัง